Bruce L Daugherty

Title: The Innovative Contributions of Bruce L Daugherty

Introduction

Bruce L Daugherty is a notable inventor based in South Orange, NJ (US). He holds three patents that reflect his significant contributions to the field of biotechnology. His work primarily focuses on methods that enhance the efficacy of therapeutic antibodies and receptors.

Latest Patents

One of Daugherty's latest patents is a method for reducing the immunogenicity of antibody variable domains. This unique method identifies and replaces immunoglobulin surface amino acid residues, converting the antigenicity of a first mammalian species to that of a second. The method effectively changes immunogenicity while preserving ligand binding properties. The judicious replacement of exterior amino acid residues does not affect ligand binding but greatly alters immunogenicity. Another significant patent is related to the eosinophil eotaxin receptor, which has been isolated, cloned, and sequenced. This receptor, designated as CC CKR3, is a human β-chemokine receptor. It may be used to screen and identify compounds that bind to the eosinophil eotaxin receptor, which could be beneficial in treating atopic conditions such as allergic rhinitis, dermatitis, conjunctivitis, and bronchial asthma.

Career Highlights

Throughout his career, Daugherty has worked with prominent companies, including Merck & Company, Inc. His experience in the pharmaceutical industry has allowed him to contribute to significant advancements in medical research and therapeutic development.

Collaborations

Daugherty has collaborated with notable colleagues, including George E Mark, III and Eduardo Agustin Padlan. These collaborations have further enriched his research and innovation efforts.

Conclusion

Bruce L Daugherty's innovative work in biotechnology has led to important advancements in the understanding and treatment of various medical conditions. His patents demonstrate a commitment to improving therapeutic methods and enhancing patient care.